Bone Fibrous Dysplasia
Conditions
Brief summary
Fibrous dysplasia is a rare bone disease which can cause pain and fractures. It has been shown that periostin is over expressed in fibrous component in patients bones ; but periostin has never been measured out in serum of patients, although it is easy to assess. This study aims to show whether serum periostin is elevated in serum of patients with fibrous dysplasia, and if it is more elevated in patients with severe forms of the disease.
Interventions
BIOLOGICALBlood sampling
Patients with bone fibrous dysplasia will have blood sampling to assess periostin rate in serum
Sponsors
Hospices Civils de Lyon
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* patients with fibrous dysplasia of the bone * access to social security * informed consent
Exclusion criteria
* no informed consent * pregnancy * patients with a history of conditions known to increase periostin serum (stade IV cancer, severe asthma, pulmonary fibrosis…)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Periostin rate in serum | At inclusion |
Secondary
| Measure | Time frame |
|---|---|
| Periostin rate in serum according to the number of fibrotic bones | At inclusion |
| Periostin rate in serum in patients with severe phenotype of the disease | At inclusion |
| Periostin rate in serum in patients with Mac Cune Albright syndrome | At inclusion |
Countries
France
Outcome results
None listed